2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Nasopharyngeal Carcinoma
39
Carcinoma, Non-Small-Cell Lung
30
Esophageal Squamous Cell Carcinoma
23
Carcinoma, Hepatocellular
23
Triple Negative Breast Neoplasms
19
Breast Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
17
Advanced Solid Tumor
17
Melanoma
15
Stomach Neoplasms
14
Small Cell Lung Carcinoma
13
Colorectal Neoplasms
13
Uterine Cervical Neoplasms
12
Neoplasms
10
Carcinoma, Transitional Cell
10
Carcinoma, Renal Cell
10
Recurrence
9
Head and Neck Neoplasms
8
Solid Tumor
7
Sarcoma
7
Neoplasm Metastasis
7
Liver Neoplasms
7
Esophageal Neoplasms
6
Urinary Bladder Neoplasms
5
Rectal Neoplasms
5
Advanced Solid Tumors
5
Pancreatic Neoplasms
4
Nasopharyngeal Neoplasms
4
Laryngeal Neoplasms
4
Hypopharyngeal Neoplasms
4
Interventions
toripalimab
1
pembrolizumab
1
Platinum Compounds
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
×
toripalimab
×
Clear all
NCT07251582
2025-11-26
LungTime-C02
Hunan Province Tumor Hospital
Phase 3
Recruiting
156 enrolled